First trial of RXR agonist

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204.

IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204. In preclinical studies, the orally bioavailable RXR agonist was effective in models of non-small-cell lung cancer and breast cancer.

Articles in this issue
Immunotherapy agent promising in NSCLC
NCCN greenlights nilotinib for imatinib-resistant CML patients
No overall survival benefit for dose-intense regimen in SCLC
Make a note of new smoking cessation codes
Relistor for treating OIC
Experts argue against need for phase III proton Rx trials
Spotlight on Cancer Centers
Novel peptide vaccine promising in myeloid leukemia
Masters of hematology and oncology: Father of tamoxifen a Brit to the core
Intensive imatinib/chemo ups EFS in pediatric Ph+ ALL
Relapsing DLBCL patients respond to rituximab-based Rx
Who’s News
From the Editor
New compound inhibits Src family kinases
Are two binding sites better than one?
Recent Videos
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Related Content
The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications

Russ Conroy
October 29th 2024
Article

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer

IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer

Russ Conroy
October 28th 2024
Article

Phase 1 expansion data may support potential combination development for IDE397 in NSCLC and urothelial cancer harboring MTAP deletions.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

ONCOLOGY Staff
October 27th 2024
Article

A panel of experts in multiple myeloma discussed strategies for monitoring and mitigating adverse effects associated with GPRC5D-targeting bispecific agents.

Findings from 3 studies combining birth and cancer registers showed postponing childbearing partially correlated with cancer increases in pregnant women.

Maternal Risks Appear Low Despite Increases in Cancer During Pregnancy

Roman Fabbricatore
October 26th 2024
Article

Findings from 3 studies combining birth and cancer registers showed postponing childbearing partially correlated with cancer increases in pregnant women.